Obacunone Alleviates Inflammatory Pain by Promoting M2 Microglial Polarization and by Activating Nrf2/HO-1 Signaling Pathway
DOI: https://doi.org/10.2147/dddt.s451281
IF: 4.3188
2024-04-19
Drug Design Development and Therapy
Abstract:Fubei Nan, Qingxin Tian, Shuangdong Chen Department of Anesthesiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China Correspondence: Shuangdong Chen, Department of Anesthesiology, the First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang, 325035, People's Republic of China, Tel +8613732058295, Email Background: Treating inflammatory pain (IP) continues to pose clinical challenge, because of the lack of effective pharmacological interventions. Microglial polarization serves as pivotal determinant in IP progress. Obacunone (OB), a low-molecular-weight compound with a diverse array of biological functions, having reported as an activator of nuclear factor E2-related factor 2 (Nrf2), exhibits anti-inflammatory property. However, it remains uncertain whether OB can alleviate IP by facilitating the transition of microglial polarization from the M1 to M2 state through modulating Nrf2/ heme oxygenase-1 (HO-1) pathway. Methods: We induced an mice IP model by subcutaneously administering Complete Freund's Adjuvant (CFA) into the hind paw. Paw withdrawal latency (PWL) in seconds (s) and paw withdrawal frequency (PWF) were employed to evaluate the establishment of the IP model, while a caliper was used to measure the maximal dorsoventral thickness of the mice paw. Nerve injury was assessed by Hematoxylin-Eosin (HE) Staining. Western blot and got conducted for detection of M1/M2 microglial polarization markers, Nrf2 and HO-1 in spinal cord tissues respectively. Results: In comparison to the control cohort, PWF, M1 phenotype marker iNOS, CD86, paw thickness increased significantly within CFA cohort, while PWL, M2 phenotype marker Arg-1, interleukin-10 (IL-10) decreased in the CFA group. In comparison to model cohort, OB treatment decreased PWF, paw thickness, M1 phenotype marker iNOS, CD86 significantly, while PWL, M2 phenotype marker Arg-1, IL-10, Nrf2, HO-1 increased significantly. The morphological injuries of sciatic nerve in CFA mice were obviously improved by OB treatment. OB inhibited the release of M1-related IL-1β, CXCL1 but promoted M2-related TGF-β, IL-10 in serum in CFA mice. The intervention of the Nrf2 inhibitor ML385 mitigated analgesic effect of OB. Conclusion: We demonstrate that OB is able to attenuate inflammatory pain via promoting microglia polarization from M1 to M2 and enhancing Nrf2/HO-1 signal. OB treatment may be a potential alternative agent in the treatment of IP. Keywords: inflammatory pain, obacunone, Nrf2, HO-1 Pain serves as a sentinel, alerting us to potential or actual tissue damage and triggering an adaptive protective response. 1 When peripheral tissues are subjected to noxious stimuli, it leads to pain hypersensitivity through primary sensory neurons peripheral sensitization. 2,3 CFA activates cellular immune responses and boosts the generation of immunoglobulins, thereby acting as an immune enhancer. 4,5 CFA-induced responses above result in inflammation in tissue within injected area, as well as cytokines release. 6 Microglia are macrophage-like cells in central nervous system (CNS), holding homeostasis within brain, as well as spinal cord. A growing body of evidence from previous research indicates that, microglia serve as pivotal determinant within pain pathogenesis. 7–9 Evidence supported, microglia/macrophages exhibit high plasticity and adapt their phenotypes in response to diverse microenvironmental cues, including proinflammatory and anti-inflammatory signals. 10 The pro-inflammatory M1-like phenotype, typified by specific biomarker expression, inclusive of nitric oxide synthase (iNOS) and CD86, tends to release harmful mediators. In contrast, the anti-inflammatory M2-like phenotype, defined by molecular signatures like CD206 and interleukin-10 (IL-10), produces beneficial mediators. 11 Multiple studies have demonstrated that encouraging a shift in microglia from the M1 to the M2 state could hold promise as a therapy for inflammatory pain (IP) treatment. 12–14 Nuclear factor E2-related factor 2 (Nrf2) has been commonly recognized as the key transcription factor that regulates inflammation and oxidative stress in pain. 15 Nrf2 resides in the cytoplasm controlled within normal conditions, where it is retained by associating with Kelch-like ECH-associated protein 1 (Keap-1). However, in response to harmful insults, it dissociates from Keap-1, subsequently translocating to the nucleus, prompting the transcription of enzymes being antioxidant and anti-inflammatory, including heme oxygenase-1 (HO-1), thus modulating the inflammatory process. 16 Previous studies have affirmed anti-i -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal